Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem

Sir,

Febrile episodes in profoundly neutropenic patients in the absence of a bacteriological diagnosis require empirical therapy with broad spectrum antimicrobials. In many centres this initial therapy comprises a combination of a β-lactam (ureidopenicillin or extended spectrum cephalosporin) and an aminoglycoside. Recently, the new antibiotic, imipenem (a formimidoyl thienamycin), has been advocated as sole therapy in this condition. Although this antibiotic has activity against a very large number of bacteria, strains of Pseudomonas (Xanthomonas) maltophilia are usually not susceptible to this agent.

Pseudomonas maltophilia is increasingly recognized as an opportunistic pathogen in immuno-compromised patients and is associated in these individuals with a wide variety of infections, including septicaemia. Recently, we have seen 9 episodes of septicaemia caused by this bacterium, one in association with ecthyma gangrenosum. Seven female patients all with haematological malignancies were affected. Biochemical typing, antibiograms and epidemiological data suggested that a common infecting strain was not involved. All 9 isolates were resistant to imipenem; however, 6 were susceptible to all aminoglycoside antibiotics. The 3 strains resistant to aminoglycoside antibiotics were susceptible to cefazidime. Only one patient had received imipenem prior to the septicaemic episode observed.

The increasing frequency of Ps. maltophilia infections in debilitated patients may limit the use of imipenem in the empirical therapy of febrile episodes. In addition, the use of imipenem in such patients for the treatment of other infections may select for the carriage of Ps. maltophilia in the gastrointestinal tract and other sites, such as respiratory tract. During episodes of profound neutropenia Ps. maltophilia colonizing such patients may then cause septicaemia which will not be adequately treated with imipenem. For example, Bodey et al. describe a case of intercurrent septicaemia due to this organism in a cancer patient receiving imipenem. As only one of our patients received imipenem before developing septicaemia, it may be that other antibiotics select for gut carriage or that Ps. maltophilia is more commonly present in the gut flora than previously supposed.

Currently, we are investigating the faecal carriage of this organism in patients with and without haematological malignancies and the effect of imipenem on this carriage.

K.G. Kerr
P.M. Hawkey
J.A. Child
D.R. Norfolk
A.W. Anderson

Department of Microbiology, University of Leeds, Leeds, LS1 2JF;
Department of Haematology, The General Infirmary at Leeds, LS1 3EX and
Department of Microbiology, York District Hospital, York YO3 7HE, UK.

References

Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem.

K. G. Kerr, P. M. Hawkey, J. A. Child, D. R. Norfolk and A. W. Anderson

Postgrad Med J 1990 66: 1090
doi: 10.1136/pgmj.66.782.1090

Updated information and services can be found at:
http://pmj.bmj.com/content/66/782/1090.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/